BioPharma Dive: HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger

This article reports on Addimmune’s strategic decision to merge with a special purpose acquisition company (SPAC), paving the way for public listing. As the HIV division of American Gene Technologies, we believe this transaction will provide essential resources to accelerate our mission to develop a transformative gene therapy for HIV.

The merger with 10X Capital Venture Acquisition Corp. III will support the clinical development of our groundbreaking therapy. Early trial data has been promising, hinting at the potential for a functional cure for patients living with HIV infections.

At Addimmune, we believe our innovative approach has the ability to revolutionize HIV treatment. This SPAC merger underscores our commitment to finding a cure and improving the lives of millions living with HIV globally.